Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease

Baisheng HUANG; Lanxin OU; Yingjie ZHANG; Meijie SHI; Sheng LI; Huanming XIAO; Xiaoling CHI

doi:10.3969/j.issn.1001-5256.2023.09.012

Volume 39 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(9): 2110-2116

PDF( 706 KB)

Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.09.012

Baisheng HUANG¹,
Lanxin OU¹,
Yingjie ZHANG¹,
Meijie SHI^{2, 3},
Sheng LI^{2, 3},
Huanming XIAO^{2, 3
,
,
,},
Xiaoling CHI^{2, 3}

1.
The Second Clinical Medical College of Guangzhou University of Chinese Medicine，Guangzhou 510006，China
2.
Department of Hepatology，The Second Affiliated Hospital of Guangzhou University of Chinese Medicine，Guangzhou 510120，China
3.
Department of Hepatology，Guangdong Provincial Hospital of Traditional Chinese Medicine，Guangzhou 510120，China

Research funding:

The Thirteenth Five－Year Plan for Major and Special Programs of the National Science and Technology of China (2018ZX10725506－003);

The Thirteenth Five－Year Plan for Major and Special Programs of the National Science and Technology of China (2018ZX10725505－004);

The Science and Technology Research Project of Traditional Chinese Medicine of Guangdong Provincial Hospital of Chinese Medicine (YN10101903);

The Science and Technology Research Project of Traditional Chinese Medicine of Guangdong Provincial Hospital of Chinese Medicine (YN2016XP03);

Open Project of State Key Laboratory of Dampness Syndrome of Chinese Medicine (SZ2022KF02);

Chi Xiaoling of Project of Inheritance Workshop of Famous Old Chinese Medicine Experts of State Administration of Traditional Chinese Medicine (Guozhong Pharmaceutical Human Education Letter ［2022］ No. 75);

The Fifth Batch of National Research and Training Programs for Clinical Talents of Traditional Chinese Medicine (Guozhong Pharmaceutical Human Education Letter ［2022］ No. 1)

More Information

Corresponding author: XIAO Huanming， xiaohuanming@163.com （ORCID： 0000－0002－8739－0720）
Received Date: 2022-12-30
Accepted Date: 2023-02-27
Published Date: 2023-09-19

Abstract

Abstract

Objective To investigate the value of traditional noninvasive fibrosis models in the diagnosis of significant liver fibrosis in patients with chronic hepatitis B （CHB） and metabolic associated fatty liver disease （MAFLD）. Methods A total of 499 patients who underwent liver pathological examination in Department of Hepatology， Guangdong Provincial Hospital of Traditional Chinese Medicine， from September 2014 to December 2020 and met the diagnostic criteria for CHB and MAFLD were enrolled in this study. The Scheuer scoring system was used to evaluate the degree of liver fibrosis. The Mann－Whitney U test was used for comparison of normally distributed continuous data between groups. A Spearman correlation analysis was used to investigate the correlation of each noninvasive diagnostic method with the degree of liver fibrosis； the receiver operating characteristic （ROC） curve was plotted to investigate the value of FibroScan， gamma－glutamyl transpeptidase－to－platelet ratio （GPR）， aspartate aminotransferase－to－platelet ratio index （APRI）， fibrosis－4 （FIB－4）， and liver stiffness measurement－to－platelet ratio index （LPRI） in the diagnosis of CHB with MAFLD； a binary Logistic regression analysis was used to construct a combined model， and the area under the ROC curve （AUC） was compared between the combined model and the five indicators used alone. The DeLong method was used for comparison of AUC between any two noninvasive diagnostic methods. Results There were 198 patients in the group with no or mild liver fibrosis （S0－S1） and 301 patients in the group with significant liver fibrosis （S≥2）. The S≥2 group had higher clinical indicators than the S0－S1 group， with significant differences between the two groups in alanine aminotransferase， aspartate aminotransferase， gamma－glutamyl transpeptidase， total bilirubin， GPR， FIB－4， APRI， LPRI， and liver stiffness measurement （LSM）（all P<0.05）. The Spearman correlation analysis showed that GPR， FIB－4， APRI， LSM， and LPRI were positively correlated with the stage of liver fibrosis （r = 0.393， 0.414， 0.449， 0.553， and 0.580， all P<0.001）. The ROC curve analysis showed that GPR， FIB－4， APRI， LSM， and LPRI used alone had an AUC of 0.704， 0.715， 0.740， 0.787， and 0.802， respectively， in the diagnosis of significant liver fibrosis. The binary Logistic regression analysis was used to construct a combined LGAF model of GPR， FIB－4， APRI， and LSM， which had an AUC of 0.814 in the diagnosis of significant liver fibrosis. LGAF was compared with GPR， FIB－4， APRI， LSM， and LPRI， respectively， in terms of AUC， and the results showed that there was a significant difference between LGAF and all five indicators except LPRI （Z=5.184， 4.884， 4.117， and 2.120， all P<0.05）. Conclusion The five data models of FibroScan， GPR， APRI， FIB－4， and LPRI have a similar value in the diagnosis of significant liver fibrosis in CHB with MAFLD compared with the combined LGAF model， which provides reference and guidance for the application of noninvasive assessment of liver fibrosis in clinical practice.
- Hepatitis B， Chronic,
- Non－alcoholic Fatty Liver Disease,
- Hepatic Fibrosis,
- Diagnosis

FullText(HTML)

References(37)

References

[1]	WANG CE, XU WT, GONG J, et al. Treatment of patients with nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897－ 899, 903. DOI: 10.16680/j.1671－3826.2022.09.06. 王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897－ 899, 903. DOI: 10.16680/j.1671－3826.2022.09.06.
[2]	FARRELL GC, WONG VW, CHITTURI S. NAFLD in Asia—as common and important as in the West[J]. Nat Rev Gastroenterol Hepatol, 2013, 10( 5): 307－ 318. DOI: 10.1038/nrgastro.2013.34.
[3]	MAK LY, SETO WK, HUI RW, et al. Fibrosis evolution in chronic hepatitis B e antigen－negative patients across a 10－year interval[J]. J Viral Hepat, 2019, 26( 7): 818－ 827. DOI: 10.1111/jvh.13095.
[4]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: a consensus－driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158( 7): 1999－ 2014. DOI: 10.1053/j.gastro.2019.11.312.
[5]	GONG H, LI LP. Value of Fibroscan combined with GPR, APRI, NFS or FIB－4 for progressive liver fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36( 3): 541－ 545. DOI: 10.3969/j.issn.1001－5256.2020.03.014. 龚航, 李良平. FibroScan分别与GPR、APRI、NFS、FIB－4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较[J]. 临床肝胆病杂志, 2020, 36( 3): 541－ 545. DOI: 10.3969/j.issn.1001－5256.2020.03.014.
[6]	WANG Q, XIE W, LIU L, et al. Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. Medicine(Baltimore), 2021, 100( 18): e25327. DOI: 10.1097/MD.0000000000025327.
[7]	Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182－ 191. DOI: 10.3760/cma.j.issn.1007－3418.2019.03.004. 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182－ 191. DOI: 10.3760/cma.j.issn.1007－3418.2019.03.004.
[8]	CHENG DY, LI B, JI SB, et al. Application of transient elastography in noninvasive diagnosis of liver fibrosis[J/CD]. Chin J Liver Dis(Electronic Version), 2021, 13( 4): 9－ 13. DOI: 10.3969/j.issn.1674－7380.2021.04.003. 程丹颖, 李贲, 纪世博, 等. 瞬时弹性成像技术在肝纤维化无创诊断中的应用[J/CD]. 中国肝脏病杂志(电子版), 2021, 13( 4): 9－ 13. DOI: 10.3969/j.issn.1674－7380.2021.04.003.
[9]	PARK JJ, PARK JY, KIM DY, et al. Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT[J]. Hepatogastroenterology, 2011, 58( 109): 1321－ 1327. DOI: 10.5754/hge11041.
[10]	OKAJIMA A, SUMIDA Y, TAKETANI H, et al. Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non－alcoholic fatty liver disease[J]. Hepatol Res, 2017, 47( 8): 721－ 730. DOI: 10.1111/hepr.12793.
[11]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.
[12]	ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14( 6): 889－ 919. DOI: 10.1007/s12072－020－10094－2.
[13]	GOODMAN ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases[J]. J Hepatol, 2007, 47( 4): 598－ 607. DOI: 10.1016/j.jhep.2007.07.006.
[14]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163－ 2172. DOI: 10.3969/j.issn.1001－5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163－ 2172. DOI: 10.3969/j.issn.1001－5256.2019.10.007.
[15]	LEMOINE M, SHIMAKAWA Y, NAYAGAM S, et al. The gamma－glutamyl transpeptidase to platelet ratio(GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut, 2016, 65( 8): 1369－ 1376. DOI: 10.1136/gutjnl－2015－309260.
[16]	LIN S, HUANG J, WANG M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40( 9): 2082－ 2089. DOI: 10.1111/liv.14548.
[17]	YAMAMURA S, ESLAM M, KAWAGUCHI T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J]. Liver Int, 2020, 40( 12): 3018－ 3030. DOI: 10.1111/liv.14675.
[18]	van KLEEF LA, CHOI H, BROUWER WP, et al. Metabolic dysfunction－associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3( 5): 100350. DOI: 10.1016/j.jhepr.2021.100350.
[19]	RUGIVARODOM M, PONGPAIBUL A, CHAINUVATI S, et al. Prognostic relevance of metabolic dysfunction－associated steatohepatitis for patients with chronic hepatitis B[J]. J Clin Transl Hepatol, 2023, 11( 1): 76－ 87. DOI: 10.14218/JCTH.2022.00055.
[20]	DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38( 9): 1562－ 1570. DOI: 10.1111/liv.13688.
[21]	EDDOWES PJ, SASSO M, ALLISON M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156( 6): 1717－ 1730. DOI: 10.1053/j.gastro.2019.01.042.
[22]	RIGOR J, DIEGUES A, PRESA J, et al. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB－4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population[J]. Postgrad Med, 2022, 134( 4): 435－ 440. DOI: 10.1080/00325481.2022.2058285.
[23]	HUANG CM, HU ZW, NIE YQ, et al. The value of non－invasive diagnostic model in predicting liver fibrosis in patients with chronic hepatitis B combined with non－alcoholic fatty liver disease[J]. Chin J Gastroenter Hepatol, 2019, 28( 8): 915－ 918. DOI: 10.3969/j.issn.1006－5709.2019.08.018. 黄春明, 胡中伟, 聂玉强, 等. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值[J]. 胃肠病学和肝病学杂志, 2019, 28( 8): 915－ 918. DOI: 10.3969/j.issn.1006－5709.2019.08.018.
[24]	CHEN X, GOH GB, HUANG J, et al. Validation of non－invasive fibrosis scores for predicting advanced fibrosis in metabolic－associated fatty liver disease[J]. J Clin Transl Hepatol, 2022, 10( 4): 589－ 594. DOI: 10.14218/JCTH.2021.00311.
[25]	UCAR F, SEZER S, GINIS Z, et al. APRI, the FIB－4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B[J]. Eur J Gastroenterol Hepatol, 2013, 25( 9): 1076－ 1081. DOI: 10.1097/MEG.0b013e32835fd699.
[26]	XIAO G, YANG J, YAN L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis－4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta－analysis[J]. Hepatology, 2015, 61( 1): 292－ 302. DOI: 10.1002/hep.27382.
[27]	ZHANG Z, WANG G, KANG K, et al. The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection[J]. PLoS One, 2016, 11( 4): e0152757. DOI: 10.1371/journal.pone.0152757.
[28]	LI Q, SONG J, HUANG Y, et al. The gamma－glutamyl－transpeptidase to platelet ratio does not show advantages than APRI and Fib－4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: A retrospective cohort study in China[J]. Medicine(Baltimore), 2016, 95( 16): e3372. DOI: 10.1097/MD.0000000000003372.
[29]	REN T, WANG H, WU R, et al. Gamma－glutamyl transpeptidase－to－platelet ratio predicts significant liver fibrosis of chronic hepatitis B patients in China[J]. Gastroenterol Res Pract, 2017, 2017: 7089702. DOI: 10.1155/2017/7089702.
[30]	LUO J, DU Z, LIANG D, et al. Gamma－Glutamyl Transpeptidase－to－Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease[J]. J Clin Lab Anal, 2022, 36( 8): e24596. DOI: 10.1002/jcla.24596.
[31]	HUANG CM, YANG Z, NIE YQ, et al. Prediction of liver fibrosis by gamma－glutamyl－transpeptidase－to－platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels[J]. J Prac Hepatol, 2018, 21( 6): 859－ 862. DOI: 10.3969/j.issn.1672－5069.2018.06.009. 黄春明, 杨湛, 聂玉强, 等. γ－谷氨酰转肽酶/血小板比值对血清转氨酶正常的慢性HBV感染者肝纤维化的预测价值分析[J]. 实用肝脏病杂志, 2018, 21( 6): 859－ 862. DOI: 10.3969/j.issn.1672－5069.2018.06.009.
[32]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370－ 398. DOI: 10.1016/j.jhep.2017.03.021.
[33]	Korean Association for the Study of the Liver(KASL). KASL clinical practice guidelines for management of chronic hepatitis B[J]. Clin Mol Hepatol, 2022, 28( 2): 276－ 331. DOI: 10.3350/cmh.2022.0084.
[34]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560－ 1599. DOI: 10.1002/hep.29800.
[35]	ZHANG GL, XU SC, ZENG J, et al. Optimizing the use of the gamma－glutamyl transpeptidase－to－platelet ratio and transient elastography to identify liver cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease[J]. Dis Markers, 2019, 2019: 2585409. DOI: 10.1155/2019/2585409.
[36]	LI Q, HUANG C, XU W, et al. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease[J]. Medicine(Baltimore), 2020, 99( 23): e20616. DOI: 10.1097/MD.0000000000020616.
[37]	ZHOU JL, WANG BQ, SUN YM, et al. Application value of liver stiffness measurement－to－platelet ratio index score in diagnosis of hepatitis B liver fibrosis and liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 7): 1529－ 1533. DOI: 10.3969/j. issn. 1001－5256.2022.07.014. 周家玲, 王冰琼, 孙亚朦, 等. LPRI评分在乙型肝炎肝纤维化及肝硬化中的诊断价值[J]. 临床肝胆病杂志, 2022, 38( 7): 1529－ 1533. DOI: 10.3969/j.issn.1001－5256.2022.07.014.

Relative Articles

[1]	Yu WANG, Shuang LI, Chenghai LIU. Immunological mechanism of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(12): 2538-2542. doi: 10.12449/JCH241227
[2]	Mingyue CHEN, Xiuliang ZHENG, Yaqin QIAO, Haitao SHEN, Yan LU. Effect of Toll-like receptor 4 on liver regeneration during acetaminophen-induced liver injury in mice[J]. Journal of Clinical Hepatology, 2023, 39(5): 1110-1118. doi: 10.3969/j.issn.1001-5256.2023.05.017
[3]	Yijing XIN, Yiyun CHEN, Hailin YANG, Yunhui ZHUO, Dingqi ZHANG, Fengfeng ZHOU. Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet[J]. Journal of Clinical Hepatology, 2023, 39(6): 1340-1350. doi: 10.3969/j.issn.1001-5256.2023.06.014
[4]	Zhixin TU, Yan WANG, Jianjie HUANG, Qinglong JIN. Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(4): 804-809. doi: 10.3969/j.issn.1001-5256.2023.04.010
[5]	Gerui ZHU, Yani PI, Jing WANG, Kai HUANG, Yuan PENG, Gaofeng CHEN, Chenghai LIU, Yanyan TAO. Efficacy of Astragali Radix extract in treatment of a mouse model of aristolochic acid Ⅰ-induced liver and renal injury by regulating the IL-6/STAT3 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(8): 1903-1910. doi: 10.3969/j.issn.1001-5256.2023.08.020
[6]	Jing YANG, Suxin LI, Yuehui ZHANG, Luhao LI, Zhaochen LIU, Dongqi SHEN, Xiaowei DANG. Effect of metformin on liver fibrosis in a mouse model of Budd-Chiari syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 2034-2039. doi: 10.3969/j.issn.1001-5256.2022.09.017
[7]	Hao TANG, Yixiao YIN, Wei LIU, Yi FANG, Jun WANG, Yiyang HU, Jinghua PENG. Effects of Xuefu Zhuyu decoction and its extracts on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2022, 38(12): 2728-2737. doi: 10.3969/j.issn.1001-5256.2022.12.010
[8]	Luyuan WANG, Minjie JIANG, Pujun GAO. Association between human leukocyte antigen gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(2): 475-479. doi: 10.3969/j.issn.1001-5256.2021.02.048
[9]	Shuai CHEN, Changqing YANG. Drug-induced liver injury: Advances and confusions in treatment[J]. Journal of Clinical Hepatology, 2021, 37(11): 2505-2509. doi: 10.3969/j.issn.1001-5256.2021.11.001
[10]	Wang YU, Lijiu ZHANG, Yan LU, Shasha SONG. Role of STAT3 in hepatocyte regeneration after acetaminophen-induced hepatocellular injury in mice[J]. Journal of Clinical Hepatology, 2021, 37(4): 857-862. doi: 10.3969/j.issn.1001-5256.2021.04.026
[11]	Tiantian GONG, Shaogang HUANG, Ruizhen SUN, Jingling SHEN, Qiuming LI, Lei LEI, Zhiyan SHAN. Effect of macrophages on the differentiation of mouse induced pluripotent stem cells into hepatic progenitor cells[J]. Journal of Clinical Hepatology, 2021, 37(4): 852-856. doi: 10.3969/j.issn.1001-5256.2021.04.025
[12]	Xuling LIU, Guangyue YANG, Wei ZHANG, Tiantian SUN, Wenting MA, Liu WU, Dongying XUE, Cheng LIU, Le TAO. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. Journal of Clinical Hepatology, 2021, 37(11): 2563-2568. doi: 10.3969/j.issn.1001-5256.2021.11.016
[13]	Peiling YE, Hongyun JIA, Liang PENG. Mechanism of action of GP73 in the regulation of liver cancer: An analysis based on transcriptome sequencing[J]. Journal of Clinical Hepatology, 2021, 37(8): 1861-1866. doi: 10.3969/j.issn.1001-5256.2021.08.022
[14]	Ji TongTong, Lu HaiYing, Tan Ning, Yu YanYan, Xu XiaoYuan. A comparative analysis of the clinical features of acute and chronic drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(7): 1556-1561. doi: 10.3969/j.issn.1001-5256.2020.07.021
[15]	Zhang Yu, Shao YueMing, Qin TingTing, Yin Xin, Wen XiaoYu. Current research status and application value of cytokines in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(8): 1883-1886. doi: 10.3969/j.issn.1001-5256.2020.08.045
[16]	Wang QiaoLing, Zou ZhengSheng. Association between cytochrome P450 gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1150-1153. doi: 10.3969/j.issn.1001-5256.2020.05.045
[17]	Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028
[18]	Xing Lu, Wang Yu, Tao YanYan, Liu ChengHai. Clinical evaluation and prognosis prediction of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(12): 2820-2823. doi: 10.3969/j.issn.1001-5256.2019.12.039
[19]	Wang Hu, Cheng Yujia, Wang Li, Liao Yifeng, Cao Jiang. Interventional effect of mangiferin on carbon tetrachloride-induced hepatic fibrosis in mice[J]. Journal of Clinical Hepatology, 2019, 35(4): 808-812. doi: 10.3969/j.issn.1001-5256.2019.04.020
[20]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	程庆兵，汪海宣，郑正，袁杰，杨彬，王玮，张亚中. 超高效液相色谱-串联质谱法测定丹桂香颗粒中马兜铃酸Ⅰ. 化学分析计量. 2024(11): 52-57 .
2.	沈婷婷，朱哿瑞，王帆，孙鑫，黄恺，彭渊，陶艳艳，刘成海. 基因表达谱分析非酒精性脂肪性肝病中谷胱甘肽转移酶的作用. 临床肝胆病杂志. 2023(01): 89-96 . 本站查看
3.	王义翠，刘延鑫，林华忠，魏炳琦，刘曹露，周茜如，赵梦瑶，徐华明. 四氯化碳诱导慢性肝损伤模型小鼠的转录组学分析. 黑龙江畜牧兽医. 2023(05): 65-69 .
4.	朱哿瑞，皮亚妮，王静，黄恺，彭渊，陈高峰，刘成海，陶艳艳. 黄芪提取物调节IL-6/STAT3信号通路治疗马兜铃酸Ⅰ诱导肝肾损伤小鼠模型的效果观察. 临床肝胆病杂志. 2023(08): 1903-1910 . 本站查看
5.	庞逸辉，李岳，张宪. 高效液相色谱法测定杜仲壮骨丸中马兜铃酸A. 化学分析计量. 2022(06): 50-53 .
6.	赵晨阳，吴倩，张云波，李刚，那晓琳. 苯并[b]荧蒽亚急性经口染毒的大鼠肝脏毒性以及转录组改变. 环境卫生学杂志. 2022(11): 777-784+789 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (411) PDF downloads(49)

Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.09.012